| 1. |
- Meyer, E., et al.
(författare)
-
The state of the art in beyond 5G distributed massive multiple-input multiple-output communication system solutions
- 2022
-
Ingår i: Open Research Europe. - : F1000 Research Ltd. - 2732-5121. ; 2
-
Forskningsöversikt (refereegranskat)abstract
- Beyond fifth generation (5G) communication systems aim towards data rates in the tera bits per second range, with improved and flexible coverage options, introducing many new technological challenges in the fields of network architecture, signal pro- cessing, and radio frequency front-ends. One option is to move towards cell-free, or distributed massive Multiple-Input Multiple-Output (MIMO) network architectures and highly integrated front-end solutions. This paper presents an outlook on be- yond 5G distributed massive MIMO communication systems, the signal processing, characterisation and simulation challenges, and an overview of the state of the art in millimetre wave antennas and electronics.
|
|
| 2. |
- O'Connor, C. M., et al.
(författare)
-
Effect of nesiritide in patients with acute decompensated heart failure
- 2011
-
Ingår i: The New England journal of medicine. - : Massachusetts Medical Society. - 0028-4793 .- 1533-4406. ; 365:1, s. 32-43
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: Nesiritide is approved in the United States for early relief of dyspnea in patients with acute heart failure. Previous meta-analyses have raised questions regarding renal toxicity and the mortality associated with this agent. METHODS: We randomly assigned 7141 patients who were hospitalized with acute heart failure to receive either nesiritide or placebo for 24 to 168 hours in addition to standard care. Coprimary end points were the change in dyspnea at 6 and 24 hours, as measured on a 7-point Likert scale, and the composite end point of rehospitalization for heart failure or death within 30 days. RESULTS: Patients randomly assigned to nesiritide, as compared with those assigned to placebo, more frequently reported markedly or moderately improved dyspnea at 6 hours (44.5% vs. 42.1%, P=0.03) and 24 hours (68.2% vs. 66.1%, P=0.007), but the prespecified level for significance (P
|
|
| 3. |
- Fanaroff, Alexander C., et al.
(författare)
-
Antithrombotic agents for secondary prevention after acute coronary syndromes : A systematic review and network meta-analysis
- 2017
-
Ingår i: International Journal of Cardiology. - : ELSEVIER IRELAND LTD. - 0167-5273 .- 1874-1754. ; 241, s. 87-96
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Nine oral antithrombotic medications currently available in the United States and Europe have been studied in clinical trials for secondary prevention of cardiac events following acute coronary syndrome (ACS). Few combinations of these medications have been directly compared, and studies have used multiple different comparator regimens.Methods: We performed a systematic review and network meta-analysis of randomized controlled trials evaluating one or more available oral antithrombotic therapies in patients with ACS or prior myocardial infarction (MI). Co-primary outcomes were all-cause and cardiovascular mortality compared with imputed placebo and aspirin monotherapy.Results: Forty-seven studies (196,057 subjects) met inclusion criteria and were included in the systematic review. Almost all studies tested either aspirin monotherapy compared with placebo or a combination of antithrombotic agents that included aspirin. Nearly all regimens reduced all-cause and cardiovascular mortality compared with imputed placebo. However, compared with imputed aspirin monotherapy, only combination therapy with aspirin plus ticagrelor was associated with lower cardiovascular mortality (OR 0.80, 95% CI 0.68-0.93), and triple therapy with aspirin, clopidogrel, and very low dose rivaroxaban was associated with lower all-cause mortality (OR 0.67, 95% CI 0.49-0.90). Major bleeding was increased 45-95% with dual antithrombotic therapy, and 2-6-fold with triple therapy.Conclusion: Few combinations of antithrombotic therapy were associated with a reduction inmortality compared with aspirin monotherapy, highlighting the difficulty in clinical interpretation of composite ischemic endpoints. Future studies may need to focus on limiting the number of antithrombotic therapies tested in combination to best balance ischemic event reduction and bleeding.
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
- Hasselblad, Serena K. R.
(författare)
-
Optimization methods for sedimentation and denitrification in activated sludge
- 1999
-
Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
- Denitrification on readily biodegradable carbon compounds and separation of biological sludge from effluent water are examples of critical sub-processes for nitrogen removal in activated sludge. The aim of this thesis was to find operational strategies and newmethods to optimize these processes. A simple method to measure the content of readily biodegradable organic matter in wastewater is presented in the thesis. Also a work on intermittent addition of carbon to a pre-denitrifying system is included. In this work it was shown that despite regular 5-day interruptions in ethanol supply, the bacteria maintained a sufficiently high denitrification capacity. The second and major part of the thesis deals with separation of biological sludge from effluent water. It includes two methods to decide and monitor the limiting solids flux; firstly by comparing the curvesof solids flux and sludge blanket heights visually and secondly by comparing real and simulated sludge blanket height curves. The simulated curve is predicted by a recursively estimated first order linear difference equation model. The second part of thethesis also include a calibration method for one-dimensional sludge settling models, to be used for simulations of sedimentation performance in a rectangular clarifier. Results from simulations agreed well with full-scale performance. Finally, a statistical analysisof variations in sludge settling capacity showed that a single floc characteristic parameter value could only explain about 15% of the variation. With the use of multivariate statistics, 45% of the variation could, with very high significance, be explained by the parameters total extended filament length, floc compactness andextracellular polymer substance abundance.
|
|
| 7. |
- Hernandez, A. F., et al.
(författare)
-
Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF)
- 2009
-
Ingår i: Am Heart J. - 1097-6744. ; 157:2, s. 271-7
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: Acute decompensated heart failure (ADHF) is a major public health burden with significant mortality and morbidity. Nesiritide is a recombinantly produced intravenous formulation of human B-type natriuretic peptide that promotes vasodilation and increases salt and water excretion, which results in reduced cardiac filling pressures. Prior studies have shown that dyspnea is improved in patients with ADHF 3 hours after nesiritide infusion with significant dose-related reductions in cardiac filling pressures and systemic vascular resistance without significant arrhythmias. However, the effect of nesiritide on dyspnea at 6 or 24 hours is unknown, and no clinical outcome trials have been done to provide a reliable estimate of the effect of nesiritide on morbidity and mortality. METHODS: The Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure trial (ASCEND-HF) is a phase III study evaluating the efficacy and safety of nesiritide in patients with ADHF. Patients hospitalized for hear failure will be randomly assigned to receive either intravenous nesiritide or matching placebo for 24 hours to 7 days. The 2 coprimary end points are (1) assessment of acute dyspnea at 6 or 24 hours and (2) death or rehospitalization for hear failure within 30 days. A total of 7,000 patients will be enrolled worldwide between 2007 and 2010. CONCLUSIONS: The data from the ASCEND-HF trial will establish whether nesiritide safely improves acute dyspnea as well as morbidity and mortality at 30 days.
|
|
| 8. |
- Sandberg, Ann-Sofie, et al.
(författare)
-
Alginate, small bowel sterol excretion, and absorption of nutrients in ileostomy subjects
- 1994
-
Ingår i: American Journal of Clinical Nutrition. - 0002-9165 .- 1938-3207. ; 60:5, s. 751-756
-
Tidskriftsartikel (refereegranskat)abstract
- The effect of alginate on ileostomy excretion of sterols and nutrients was investigated in six ileostomy subjects fed a constant low-fiber diet with or without supplementation with 7.5 g sodium alginate. A mean of 95% of uronic acids derived from the sodium alginate was recovered in the ileostomy contents. Supplementation with alginate increased fat excretion by 140% and decreased bile acids excretion by 12%. Sodium and potassium excretion were significantly increased whereas starch and nitrogen excretion were unchanged. Five of six subjects showed a decreased apparent absorption of iron and manganese with alginate, which, however, was not statistically significant. Absorption of phosphorus, calcium, magnesium, and zinc were unchanged. Almost no digestion of sodium alginate occurs in the stomach and small intestine. The increased fatty acids excretion may be explained by the binding or trapping of fatty acids in the gel matrix formed by alginate, which may also cause a reduced bile flow.
|
|
